1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Novartis' MenB vaccine Bexsero set for blockbuster status after new data

 
• By Haylyn Wong

Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.

Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.

The head of meningococcal vaccines at Novartis, Dr Peter Dull, presented an overview of the Phase III clinical trial results...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapeutic Category

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.